EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Transition From Intraoperative Vancomycin‐Piperacillin Tazobactam to Vancomycin‐Cefepime Does Not Change Acute Kidney Injury or Renal Recovery Outcomes in Patients Undergoing Heart Transplantation

Ashley L Golbus iD, Syed Quadri, Elaine Park, Courtney E Harris iD, Patrick T Murray, Arman Kilic, Ryan J Tedford, Rupak Mukherjee iD, Blaithin A McMahon

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Ashley L Golbus und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Vancomycin, Acute Kidney Injury, Anti-Bacterial Agents, Heart Transplantation. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: DCI, Duke Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The impact of empiric intraoperative vancomycin and piperacillin‐tazobactam (VPT) compared to vancomycin and cefepime (VC) on AKI is equivocal, and renal recovery and infection outcomes have not been studied in this context. Further, this has not been studied in patients undergoing orthotopic heart transplantation (OHT).

Methods

We performed a single‐center prospective study in patients undergoing OHT ( n = 120), with a change in intraoperative microbial coverage from VPT to VC. Primary outcomes included AKI rates and stage. Secondary outcomes included renal recovery rates, bloodstream bacterial infections, rates of enterococcal infection, ESRD (end‐stage renal disease), change in eGFR, and mortality at 12 months post‐OHT.

Results

Rates of all stages of AKI were similar between groups ( p = 0.769), and the majority of AKI in both groups were Stage 1. 27.1% of patients in the pre‐intervention arm and 25.0% in the post‐intervention arm had a Stage 3 AKI ( p = 0.798). Rates of recovery from AKI at 7 days showed a trend toward improved recovery in patients receiving VC compared to VPT (65.1%, 46.7%, p = 0.056), but recovery from RRT at 7 days and recovery from RRT at hospital discharge were not statistically significant between groups ( p = 0.140, p = 0.659). Rates of bloodstream infection were similar following the change in empiric antimicrobials (2.08%, 4.17%; p = 0.53), and rates of wound infection were similar following this change (4.2%, 1.4%; p = 0.56). There was no increase in enterococcal infections.

Conclusion

In patients undergoing OHT and receiving empiric antimicrobial therapy, change from VPT to VC did not affect the incidence or severity of AKI, renal recovery, or infection rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinAcute Kidney InjuryAnti-Bacterial AgentsHeart TransplantationPostoperative ComplicationsHumansMaleFemaleMiddle AgedProspective StudiesPrognosisFollow-Up StudiesPiperacillin, Tazobactam Drug CombinationCefepimeRisk FactorsIntraoperative CareAgedGlomerular Filtration RateAdultKidney Function Tests

Stichwörter der Autor:innen

acute kidney injuryantimicrobialnephrotoxicityorthotopic heart transplantationrenal recovery

Substanzen

VancomycinAnti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationCefepime

Autor:innen und Institutionen

  • College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • School of Medicine, University College Dublin, Dublin, Ireland.
  • Division of Cardiothoracic Surgery, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.

ORCID-Profile: Ashley L Golbus, Courtney E Harris, Rupak Mukherjee

Förderung

  • DCI
  • Duke Cancer Institute

Zitieren

APA

Golbus, A. L., Quadri, S., Park, E., Harris, C. E., Murray, P. T., Kilic, A., Tedford, R. J., Mukherjee, R., & McMahon, B. A. (2025). Transition From Intraoperative Vancomycin‐Piperacillin Tazobactam to Vancomycin‐Cefepime Does Not Change Acute Kidney Injury or Renal Recovery Outcomes in Patients Undergoing Heart Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70213

Vancouver

Golbus AL, Quadri S, Park E, Harris CE, Murray PT, Kilic A, et al. Transition From Intraoperative Vancomycin‐Piperacillin Tazobactam to Vancomycin‐Cefepime Does Not Change Acute Kidney Injury or Renal Recovery Outcomes in Patients Undergoing Heart Transplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70213

BibTeX
@article{Golbus2025,
  author = {Golbus, Ashley L and Quadri, Syed and Park, Elaine and Harris, Courtney E and Murray, Patrick T and Kilic, Arman and Tedford, Ryan J and Mukherjee, Rupak and McMahon, Blaithin A},
  title = {Transition From Intraoperative Vancomycin‐Piperacillin Tazobactam to Vancomycin‐Cefepime Does Not Change Acute Kidney Injury or Renal Recovery Outcomes in Patients Undergoing Heart Transplantation},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70213}
}
Kostenlos starten →